MARKET

AKTX

AKTX

Akari
NASDAQ

Real-time Quotes | Nasdaq Last Sale

1.370
-0.080
-5.52%
After Hours: 1.370 0 0.00% 17:16 04/01 EDT
OPEN
1.410
PREV CLOSE
1.450
HIGH
1.505
LOW
1.340
VOLUME
106.08K
TURNOVER
--
52 WEEK HIGH
5.04
52 WEEK LOW
0.8700
MARKET CAP
21.66M
P/E (TTM)
-1.7792
1D
5D
1M
3M
1Y
5Y

Analyst Rating

Based on 2 analysts

Strong Buy

Disclaimer: The analysis information is for reference only and does not constitute an investment recommendation.

Analyst Price Target

The average AKTX stock price target is 6.50 with a high estimate of 8.00 and a low estimate of 5.00.

EPS

AKTX News

More
  • Akari Therapeutics reports Q4 results
  • seekingalpha · 1d ago
  • Akari Therapeutics Reports Fourth Quarter and Full Year 2019 Financial Results and Business Highlights
  • GlobeNewswire · 1d ago
  • Akari Therapeutics Q4 EPS $0.00
  • Benzinga · 1d ago
  • B. Riley FBR Maintains Buy on Akari Therapeutics, Lowers Price Target to $5
  • Benzinga · 03/13 11:29

Industry

Biotechnology & Medical Research
-4.52%
Pharmaceuticals & Medical Research
-2.91%

Hot Stocks

Symbol
Price
%Change

About AKTX

Akari Therapeutics, Plc, formerly Celsus Therapeutics Plc, is a clinical-stage biopharmaceutical company. It is focused on the development and commercialization of treatments for a range of rare and orphan autoimmune and inflammatory diseases caused by dysregulation of complement component 5 (C5), including paroxysmal nocturnal hemoglobinuria, Guillain Barre syndrome and atypical Hemolytic Uremic Syndrome. Its lead drug, Coversin, a complement inhibitor, acts on complement C5, preventing release of C5a and formation of C5b-9. Coversin is a recombinant small protein derived from a protein discovered in the saliva of the Ornithodoros moubata tick, where it modulates the host immune system to allow the parasite to feed without alerting the host to its presence or provoking an immune response. It is conducting Phase Ib clinical trial of Coversin. It focuses on rare and orphan diseases, including disease states spanning hematology, nephrology, transplantation, neurology and ophthalmology.
More

Webull offers kinds of Akari Therapeutics PLC (ADR) stock information, including NASDAQ:AKTX real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, AKTX stock news, and many more online research tools to help you make informed decisions.